Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 9/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697492 | 0.85 | BTK (0.56) | TGM2BTKEGFR | |
| SCHEMBL13170055 | 0.84 | PLK4 (0.54) | EGFR | |
| SCHEMBL13169893 | 0.80 | PLK4 (0.49) | BTKEGFR | |
| SCHEMBL13170050 | 0.80 | PLK4 (0.61) | TGM2BTKEGFR | |
| SCHEMBL13170045 | 0.79 | ITK (0.51) | BTKFGFR1FGFR4EGFR | |
| SCHEMBL13170072 | 0.79 | TGM2 (0.53) | TGM2BTKEGFR | |
| SCHEMBL13169472 | 0.77 | ITK (0.53) | TGM2BTKEGFR | |
| SCHEMBL3693031 | 0.76 | TGM2 (0.56) | TGM2LMNABTKEGFR | |
| SCHEMBL13169555 | 0.76 | PLK4 (0.46) | BTKFGFR4EGFR | |
| SCHEMBL13169463 | 0.76 | TGM2 (0.56) | TGM2LMNABTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114900-B1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2018-10-10 | — | — | EP | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| EP-2114900-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092199-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885F13A1 3880/4885LMNA 4873/4885 |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885F13A1 3880/4885LMNA 4873/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | TGM2 965/4885F13A1 3880/4885LMNA 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.